Gilead Sciences Newswire

Comprehensive Real-Time News Feed for Gilead Sciences.

Results 1 - 20 of 881 in Gilead Sciences

  1. Bio Ceo Program to highlight latest in clinical development.Read the original story

    Thursday Jan 22 | ThomasNet

    ... of the Board and CEO, Pfizer Tuesday, February 10, 3:30 4:25 pm John F. Milligan, PhD, President and COO, Gilead Sciences Tuesday, February 10, 10:00 10:55 am John Maraganore, PhD, CEO, Alnylam Tuesday, February 10, 11:00 11:55 am Peter Greenleaf, ...

    Comment?

  2. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    7 hrs ago | Business Wire

    )--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2014 financial results will be released on Tuesday, February 3, at 4... UMB Financial Corporation Reports Fourth Quarter Net Income of $26.9 Million and ...

    Comment?

  3. Mylan expands Hepatitis C licensing agreement with GileadRead the original story

    12 hrs ago | Newkerala.com

    Mylan Inc. on Tuesday announced that its subsidiary Mylan Laboratories Limited is expanding its hepatitis C licensing agreement with Gilead Sciences, Inc. to include the non-exclusive rights to manufacture and distribute the investigational NS5A inhibitor GS-5816 and single tablet regimen of sofosbuvir/GS-5816, once approved, in 91developing countries. The single tablet regimen is being evaluated in Phase 3 clinical studies for the treatment of all six genotypes of hepatitis C. If approved by regulatory authorities, the sofosbuvir/GS-5816 regimen would become the first all-oral single tablet regimen for all hepatitis C genotypes.

    Comment?

  4. Gilead Sciences to Release Fourth Quarter and Full Year 2014...Read the original story

    16 hrs ago | Freshnews

    Gilead Sciences, Inc. announced today that its fourth quarter and full year 2014 financial results will be released on Tuesday, February 3, at 4:05 p.m. Eastern Time. At 4:30 p.m. Eastern Time, Gilead's management will host a conference call to discuss the company's financial results for the fourth quarter and full year 2014 as well as provide a general business update and financial guidance for 2015.

    Comment?

  5. New market study, "Gram-Negative Bacterial Infections Global Clinical ...Read the original story

    23 hrs ago | PR-inside.com

    ... AG Clinical Trial Overview of Novartis AG Merck & Co., Inc. Clinical Trial Overview of Merck & Co., Inc. Gilead Sciences, Inc. Clinical Trial Overview of Gilead Sciences, Inc. AstraZeneca PLC Clinical Trial Overview of AstraZeneca PLC Prokarium Ltd. ...

    Comment?

  6. This Telling Figure Insinuates Big Pharma Could Be in Big TroubleRead the original story w/Photo

    Yesterday | The Motley Fool

    ... stock being sold for every one share of stock being purchased by an insider. As you can see, the high-flying Gilead Sciences led to 48 insider sales and nearly 2.1 million shares being sold, while Eli Lilly's 20 insider sales accounted for nearly ...

    Comment?

  7. EnvisionRx and Gilead Sciences Sign Exclusive Agreement to Help in the Fight Against Hepatitis CRead the original story

    Monday | Information Technology

    EnvisionRx, a national, full-service pharmacy benefit management company, today announced a partnership with Gilead Sciences Inc., a pioneer in the treatment of the Hepatitis C virus , to provide availability to HCV infection treatments Sovaldi and Harvoni for EnvisionRx patients on an exclusive basis. "EnvisionRx is committed to helping patients attain the most effective drugs at affordable prices, and we are proud to be able to offer our patients Sovaldi and Harvoni, the market leaders in the treatment of HCV, " said Dawn Sherman, President of EnvisionRx.

    Comment?

  8. Can Mylan Inc. (MYL) Take Out $60?Read the original story

    Monday | SchaeffersResearch.com

    Generic drugmaker Mylan Inc is up 4.1% at $56.45, and is seeing some serious volume, after the firm said it expanded its contract to manufacture and distribute partner Gilead Sciences, Inc.'s hepatitis C treatments. MYL's 30-day at-the-money implied volatility has popped 8.1% to 29.1%, and call volume is running at twice the average intraday pace, pointing to a growing demand for short-term bullish bets.

    Comment?

  9. Mylan Expands Hepatitis C Licensing Agreement with Gilead to Include...Read the original story

    Monday | Freshnews

    Mylan Inc. today announced that its subsidiary Mylan Laboratories Limited is expanding its hepatitis C licensing agreement with Gilead Sciences, Inc. to include the non-exclusive rights to manufacture and distribute the investigational NS5A inhibitor GS-5816 and single tablet regimen of sofosbuvir )/GS-5816, once approved, in 91 developing countries. The single tablet regimen is being evaluated in Phase 3 clinical studies for the treatment of all six genotypes of hepatitis C. If approved by regulatory authorities, the sofosbuvir/GS-5816 regimen would become the first all-oral single tablet regimen for all hepatitis C genotypes.

    Comment?

  10. Mylan Inc. Expands Hepatitis C Licensing Agreement With Gilead...Read the original story

    Sunday | BioSpace

    ... that its subsidiary Mylan Laboratories Limited is expanding its hepatitis C licensing agreement with Gilead Sciences, Inc. to include the non-exclusive rights to manufacture and distribute the investigational NS5A inhibitor GS-5816 and single tablet ...

    Comment?

  11. Envisionrx And Gilead Sciences, Inc. Sign Exclusive Agreement To...Read the original story

    Sunday | BioSpace

    EnvisionRxA , a national, full-service pharmacy benefit management company, today announced a partnership with Gilead Sciences Inc., a pioneer in the treatment of the Hepatitis C virus , to provide availability to HCV infection treatments SovaldiA and Harvonia for EnvisionRx patients on an exclusive basis.

    Comment?

  12. Gilead Expands Hepatitis C Generic Licensing Agreements to Include...Read the original story w/Photo

    Monday | Pharmaceutical Processing

    Gilead Sciences announced that the company has expanded its hepatitis C generic licensing agreements to include the investigational NS5A inhibitor GS-5816, which is being evaluated in Phase 3 clinical studies as part of a single tablet regimen that combines the compound and sofosbuvir for the treatment of all six genotypes of hepatitis C. The expanded agreements will allow Gilead's India-based partners to manufacture GS-5816 and the single tablet regimen of sofosbuvir/GS-5816, once approved, for distribution in 91 developing countries, which together account for 54 percent of the total worldwide population of individuals infected with the hepatitis C virus .

    Comment?

  13. Gilead to Allow Drug Makers to Produce Hepatitis C TreatmentRead the original story w/Photo

    Monday | Wall Street Journal

    The hepatitis C medication Sovaldi. Gilead Sciences said it would allow generic-drug makers to produce a new version of the treatment.

    Comment?

  14. Gilead Sciences, Inc. to Allow Generic Drugmakers to Produce New Hep C DrugRead the original story

    Sunday | BioSpace

    FOSTER CITY, Calif.-- --Gilead Sciences, Inc. today announced that the company has expanded its hepatitis C generic licensing agreements to include the investigational NS5A inhibitor GS-5816, which is being evaluated in Phase 3 clinical studies as part of a single tablet regimen that combines the compound and sofosbuvir for the treatment of all six genotypes of hepatitis C. The expanded agreements will allow Gilead's India-based partners to manufacture GS-5816 and the single tablet regimen of sofosbuvir/GS-5816, once approved, for distribution in 91 developing countries, which together account for 54 percent of the total worldwide population of individuals infected with the hepatitis C virus .

    Comment?

  15. Pipeline Review of Chronic Coronary Artery Disease Therapeutics MarketRead the original story w/Photo

    Saturday Jan 24 | PRWeb

    ... that can drive projects out of the pipeline. Some of the key market players studied by the report include Gilead Sciences, Inc., Juventas Therapeutics, Inc., Human Stem Cells Institute, Nuo Therapeutics, Inc., and Lacer, S.A., among others. By ...

    Comment?

  16. Atrial Fibrillation Therapeutic Pipeline Review H1 2015 Report at...Read the original story w/Photo

    Friday Jan 23 | PRWeb

    ... Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Cardiome Pharma Corp, Daiichi Sankyo Company, Limited, Gilead Sciences, Inc.m Isis Pharmaceuticals, Inc., Laboratoires Pierre Fabre SA, Nissan Chemical Industries, Ltd., Nyken BV, Otsuka Holdings ...

    Comment?

  17. A Couple Of Things To Know Before Bringing A Piercing The Corporate Veil ClaimRead the original story w/Photo

    Friday Jan 23 | JD Supra

    You might remember the case of Cold Springs Ventures, LLC v. Gilead Sciences, Inc ..

    Comment?

  18. 3 Attractive Biotech Picks For 2015Read the original story w/Photo

    Friday Jan 23 | Seeking Alpha

    ... as I offer up three selections for 2015 in spaces that I believe have plenty of upside in the new year. Gilead Sciences (NASDAQ: GILD ) makes up some 25% of my overall allocation to the biotech and biopharma sectors, and is the single Investors seem ...

    Comment?

  19. Biocon to take Syngene unit publicRead the original story

    Thursday Jan 22 | Mydigitalfc.com

    ... 10-15 percent from Biocon's majority stake in the unit in the public offer. Separately, Biocon agreed with Gilead Sciences Inc to licence its chronic hepatitis-C product range, it said in a statement. For the three months to Dec. 31, Biocon reported ...

    Comment?

  20. India's Biocon says to take Syngene unit publicRead the original story

    Thursday Jan 22 | Reuters

    ... 10-15 percent from Biocon's majority stake in the unit in the public offer. Separately, Biocon agreed with Gilead Sciences Inc to licence its chronic hepatitis-C product range, it said in a statement. For the three months to Dec. 31, Biocon reported ...

    Comment?